Dogwood Therapeutics (DWTX) Long-Term Deferred Tax (2023 - 2025)
Dogwood Therapeutics (DWTX) posted quarterly Long-Term Deferred Tax of $485553.0 for Q4 2025, down 92.97% year-over-year from $6.9 million in Q4 2024, and down 92.97% quarter-over-quarter from $6.9 million in Q4 2024.
Dogwood Therapeutics (DWTX) Long-Term Deferred Tax (2023 - 2025) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Long-Term Deferred Tax for 3 consecutive years, with $485553.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Deferred Tax fell 92.97% year-over-year to $485553.0; the TTM figure through Dec 2025 stood at $485553.0 (down 92.97% YoY), while the FY2025 annual figure was $485553.0, down 92.97% from the prior year.
- Long-Term Deferred Tax slipped to $485553.0 in Q4 2025 per DWTX's latest filing, from $6.9 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $6.9 million in Q4 2024 and bottomed at $215622.0 in Q4 2023.
- Historically, Long-Term Deferred Tax has averaged $2.5 million across 3 years, with a median of $485553.0 in 2025.
- Annual changes were most pronounced in 2024 — Long-Term Deferred Tax surged 3101.78% — and 2025, when it sank 92.97%.
- Dogwood Therapeutics' Long-Term Deferred Tax stood at $215622.0 in 2023, then soared by 3101.78% to $6.9 million in 2024, then tumbled by 92.97% to $485553.0 in 2025.
- Business Quant data shows DWTX's Long-Term Deferred Tax at $485553.0 in Q4 2025, $6.9 million in Q4 2024, and $215622.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 485,553.00 |
| Dec 31, 2024 | 6.90 Mn |
| Dec 31, 2023 | 215,622.00 |